United Rises On Unusually High Volume (UTHR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- United Therapeutics Corporation (Nasdaq: UTHR) is trading at unusually high volume Tuesday with 1.6 million shares changing hands. It is currently at two times its average daily volume and trading up $1.80 (+2.8%) at $66.78 as of 3:50 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

United has a market cap of $3.09 billion and is part of the health care sector and drugs industry. Shares are up 15.4% year to date as of the close of trading on Monday.

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. The company has a P/E ratio of 9.8, below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates United as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full United Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

United Therapeutics, DOJ in Possible Settlement Over Drug Contributions

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Biotech Movers: Novocure, United Therapeutics, Kite Pharma

United Therapeutics Stock Slumping on Credit Suisse Rating